Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
ChiCTR1900026242Phase 4Not yet recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of low molecular weight heparin calcium in hepatic veno-occlusive disease (HVOD) (2 arms), sponsored by Huazhong University of Science and Technology. Primary endpoints: Liver function and Blood coagulation function. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
hepatic veno-occlusive disease (HVOD)
Beyond the preview
Go deeper on ChiCTR1900026242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026242.